MTF Biologics Finds Distributor for its AmnioBand Membrane

MTF Biologics has named New Horizon Medical Solutions (NHMS) as the exclusive distributor of its AmnioBand Membrane to U.S. wound care specialists, podiatrists, and mobile care practitioners.

The agreement combines AmnioBand’s peer-reviewed Level 1 clinical evidence base with NHMS’s specialized provider network and hands-on field support, creating a distribution model purpose-built for the complex realities of outpatient and mobile wound care. Clinicians gain consistent allograft access, expert point-of-care support, and the confidence of broad payer coverage through commercial and Medicare health plans reaching more than 280 million Americans.

“Wound care specialists and podiatrists deserve a solution they can trust; one backed by real clinical evidence, consistent payer access, and an uncompromising standard for quality and safety,” MTF Biologics President/CEO Joe Yaccarino said. “New Horizon Medical Solutions’ exclusive focus on this patient population and their depth of provider relationships make them the right partner to expand that access.”

NHMS was selected for its dedicated wound care model, which integrates clinical field teams, established provider relationships, and practice infrastructure specifically designed for wound care and podiatry settings. The company’s singular focus on this patient population enables a level of clinical support and practice integration that broad-line distributors cannot match.

“The wound care clinicians we work with are managing complex patients under real payer and documentation pressure. They need a tissue solution with the clinical evidence to support their treatment decisions and the coverage reliability to make it practice-viable,” New Horizon Medical Solutions CEO Will Hall stated. “AmnioBand delivers both. Our exclusive relationship ensures our providers will have consistent allograft access, expert clinical support at the point of care, and a partner they can count on now and long term.”

The agreement reflects MTF Biologics’ mission to save and heal lives by expanding patient access to evidence-supported tissue solutions. It underscores NHMS’s commitment to equipping wound care providers with the clinical tools and practice support they need to deliver better outcomes.

Key highlights of the distribution agreement:

• It positions NHMS as the sole channel partner for AmnioBand Membrane to wound care specialists, podiatrists, and mobile care practitioners focused in providing services in the outpatient setting.
• Clinical credibility: AmnioBand is supported by Level 1 peer-reviewed clinical evidence demonstrating outcomes across both DFU and VLU wound care applications.
• Broad coverage access: AmnioBand is covered by commercial and Medicare health plans, reaching more than 280 million Americans and reducing reimbursement risk for providers.
• Rigorous safety standard: MTF Biologics’ employs aseptic processing and comprehensive quality controls that support validated sterility testing.
• Dedicated field infrastructure: NHMS brings specialized clinical field teams, deep provider relationships, and hands-on practice integration support to accelerate adoption at the point of care.

AmnioBand Membrane is a bilayer amnion/chorion placental allograft processed under aseptic processing standards with rigorous quality testing. With access across more than 280 million Americans through commercial and Medicare health plans, AmnioBand offers wound care specialists broad coverage and practice efficiency across patient populations. Its clinical foundation includes peer-reviewed publications that provide clinicians with demonstrated outcomes across wound care applications.

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing science. In partnership with organ and tissue recovery organizations, MTF Biologics provides exceptional services, resources, and expertise to donors and their families; tissue and organ transplant patients; and clinicians and scientists who advance patient care.

The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized screening, coordination, and communications services to organ transplant centers, organ, tissue, and eye procurement organizations, and the hospitals and patients that they serve. Its sister organization, Deutsches Institut für Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation), expands its reach to patients across the globe.

New Horizon Medical Solutions is a forward-thinking company specializing in advanced wound care technologies, developing and delivering biologically derived human placental allograft products that meet high safety and performance standards. NHMS’s product portfolio includes amniotic tissues, micro autologous skin grafting, and wound care devices for wound imaging and debridement for chronic wounds, surgical reconstruction, burns, and orthopedic procedures. Through evidence-based design and precision manufacturing, NHMS strives to enhance patient outcomes in clinical practice.